| Literature DB >> 22108843 |
L B J van der Velden1, M Tromp, C P Bleeker-Rovers, M Hulscher, B J Kullberg, J W Mouton, P D J Sturm, P Pickkers.
Abstract
Mortality in patients admitted with sepsis is high and the increasing incidence of infections with multiresistant bacteria is a worldwide problem. Many hospitals have local antimicrobial guidelines to assure effective treatment and limit the use of broad-spectrum antibiotics, thereby reducing the selection of resistant bacteria. We evaluated adherence to the antimicrobial treatment guidelines of our hospital in patients presenting to the emergency department (ED) with sepsis and assessed the in vitro susceptibility of isolated pathogens to the guideline-recommended treatment and the prescribed treatment. We included all adult patients with a known or suspected infection and two or more extended systemic inflammatory response syndrome (SIRS) criteria. Patients who did not receive antimicrobial treatment, presented with infections not included in the guidelines, or had more than one possible focus of infection were excluded. A total of 276 ED visits (262 patients) were included. Guideline-concordant treatment was prescribed in 168 visits (61%). In the case of guideline-disconcordant treatment, 87% was more broad-spectrum than guideline-recommended treatment. A microbiological diagnosis was established in 96 visits (35%). The susceptibility of the pathogens isolated from patients treated with guideline-concordant treatment (n=68) and guideline-disconcordant treatment (n=28) to guideline-recommended treatment (91% versus 89%) and to prescribed treatment (91% versus 93%) was similar (p=0.77 and p=0.79, respectively). In conclusion, non-adherence to the guidelines occurred frequently and resulted in more broad-spectrum empirical therapy. This did not result in a higher rate of susceptibility of the isolated pathogens to the prescribed empirical therapy.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22108843 PMCID: PMC3364419 DOI: 10.1007/s10096-011-1478-5
Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN: 0934-9723 Impact factor: 3.267
Empirical antimicrobial treatment guideline recommendations for the most common infections
| Diagnosis | Guideline-recommended treatment |
|---|---|
| Urosepsis | Ceftriaxone 1 g every 24 h after a 2 g loading dose |
| Recent antibiotic usea | Ceftazidime 1 g every 8 h |
| Febrile neutropenia | Ceftazidime 2 g every 8 h |
| Meningitis | Ceftriaxone 2 g every 12 h |
| Listeria risk factors | Ceftriaxone 2 g every 12 h + amoxicillin 2 g every 4 h |
| Sepsis of unknown origin | Ceftriaxone 2 g every 24 h |
| Recent antibiotic use or hospitalizationa | Piperacillin–tazobactam 4.5 g every 8 h |
| Cholangitis | Piperacillin 4 g every 8 h |
| Skin or soft tissue infection | |
| Cellulitis | Flucloxacillin 1 g every 4 h |
| Erysipelas | Penicillin 1 million UI every 6 h or clindamycin 600 mg every 8 h |
| Pneumoniab | |
| Mild | Doxycycline 100 mg every 24 h after a 200-mg loading dose OR amoxicillin 500 mg every 6 h |
| Severe | Penicillin 1 million UI every 4 h OR penicillin 1 million UI every 4 h + ciprofloxacin 400 mg every 12 h |
| Nursing home or recent antibiotic usea | Piperacillin–tazobactam 4.5 g every 8 h |
| Aspiration pneumonia | Amoxicillin–clavulanic acid 1.2 g every 6 h |
a“Recent” was not specifically defined in the guidelines
bSeverity determined by the CURB-65 score: each risk factor scores 1 point: confusion, urea >7 mmol/L (19 mg/dL), respiratory rate ≥30/min, blood pressure systolic ≤90 mmHg and/or diastolic ≤60 mmHg , age 65 years or older. A pneumonia was considered to be mild when the score was 0–1 and severe when the score was ≥ 2
Fig. 1Flow-chart of the included emergency department visits. ED: emergency department, SIRS: systemic inflammatory response syndrome
Patient demographics and characteristics by adherence to guideline-recommended treatment
| Characteristic | Guideline-concordant treatment ( | Guideline-disconcordant treatment ( |
|
|---|---|---|---|
| Mean age, years ± SD | 59 ± 19 | 60 ± 18 | 0.55 |
| Male | 103 (61%) | 72 (65%) | 0.46 |
| Nursing home resident | 10 (6%) | 8 (7%) | 0.63 |
| Hospitalization in the last 3 months | 51 (30%) | 30 (27%) | 0.65 |
| Mean C-reactive protein ± SD | 135 ± 122 | 114 ± 112 | 0.16 |
| Mean lactate ± SD | 2.5 ± 1.4 | 2.3 ± 1.3 | 0.28 |
| BC obtained | 160 (95%) | 100 (93%) | 0.36 |
| Bacteremia | 32 (19%) | 17 (16%) | 0.48 |
| Median (IQR) LOS (days) | 6 (9) | 7 (8) | 0.90 |
| 30-day mortality | 17 (10%) | 10 (9%) | 0.77 |
| ED treatment by | <0.001 | ||
| General surgery (16) | 6 (4%) | 10 (9%) | |
| Orthopedics (2) | 0 (0%) | 2 (2%) | |
| Urology (17) | 17 (10%) | 0 (0%) | |
| Internal medicine (157) | 109 (65%) | 48 (44%) | |
| Neurology (11) | 10 (6%) | 1 (1%) | |
| Pulmonology (72) | 22 (13%) | 50 (45%) | |
| Otolaryngology (1) | 0 (0%) | 1 (1%) |
ED: emergency department, BC: blood culture, IQR: interquartile range, LOS: length of stay
Adherence to guideline-recommended treatment categorized by clinical diagnosis (n = 276)
| Clinical diagnosis | Guideline-concordant treatment ( | Guideline-disconcordant treatment ( |
|---|---|---|
| Urosepsis (42) | 40 (95%) | 2 (5%) |
| Recent antibiotic use (4) | 4 | – |
| Febrile neutropenia (17) | 16 (94%) | 1 (6%) |
| Meningitis (6) | 5 (83%) | 1 (17%) |
| Sepsis of unknown origin (29) | 21 (75%) | 8 (25%) |
| Recent antibiotic use or hospitalization (4) | 3 | 1 |
| Miscellaneous infections (19) | 12 (63%) | 7 (37%) |
| Arthritis (3) | – | 3 |
|
| 1 | 2 |
| Diverticulitis (2) | 1 | 1 |
| Pancreatitis (1) | 1 | – |
| Postpartum fever (1) | 1 | – |
| Other abdominal infections (5) | 5 | – |
| Epididymitis (1) | 1 | – |
| Endocarditis (1) | 1 | – |
| Tonsillitis (1) | – | 1 |
| Brain abscess (1) | 1 | – |
| Cholangitis (7) | 4 (57%) | 3 (43%) |
| Skin or soft tissue infection (15) | 8 (53%) | 7 (47%) |
| Cellulitis (5) | 3 | 2 |
| Erysipelas (10) | 5 | 5 |
| Pneumonia (142) | 62 (44%) | 80 (56%) |
| Mild (66) | 23 | 43 |
| Severe (41) | 22 | 19 |
| Nursing home or recent antibiotic use (31) | 16 | 15 |
| Aspiration (4) | 1 | 3 |
Isolated pathogens per diagnosis (n = 96) and the pathogens which were in vitro resistant to the guideline-recommended treatment (n = 9)
| Isolated pathogens ( | Resistant to guideline therapy ( | |
|---|---|---|
| Urosepsis (33) | Enterobacteriaceae (22) | |
|
| 2 | |
|
| ||
|
| ||
| Polymicrobial (2) | 2 ( | |
|
| ||
| Recent antibiotic use |
| |
| Pneumonia (30) |
| |
|
| ||
| Beta-hemolytic streptococci (3) | ||
|
| ||
|
| 1 | |
|
| ||
|
| ||
| Polymicrobial (1) | ||
| Aspiration pneumonia | Polymicrobial (1) | 1 ( |
| NH or recent antibiotic use |
| |
|
| ||
|
| ||
| Skin or soft tissue (3) | Beta-hemolytic streptococci (3) | |
| Meningitis (3) |
| |
| Cholangitis (4) |
| |
|
| 1 | |
|
| ||
| Polymicrobial | ||
| Sepsis of unknown origin (12) | Enterobacteriaceae (8) | |
|
| ||
|
| ||
| Polymicrobial (1) | 1 (ESBL | |
| Febrile neutropenia (6) | Enterobacteriaceae (2) | |
| Polymicrobial (2) | 1 ( | |
|
| ||
|
| ||
| Miscellaneous infections (5) | ||
| Endocarditis |
| |
| Arthritis |
| |
|
|
| |
| Other abdominal infections |
| |
| Postpartum fever |
| |
NH: nursing home resident, ESBL: extended-spectrum beta-lactamase
aThis patient was treated with ceftazidime and teicoplanin based on recent culture results and recent antibiotic use: this regimen was considered to be guideline-concordant treatment